Wall Street Has a Mixed Opinion on Astrana Health (ASTH), Here’s Why

Published on November 18, 2025 at 5:07 am by Talha Qureshi in News

Astrana Health, Inc. (NASDAQ:ASTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Astrana Health, Inc. (NASDAQ:ASTH). On November 12, Jaliendra Singh from Truist Financial reiterated a Buy rating on the stock with a price target of $37. However, earlier on November 10, Ryan Langston from TD Cowen lowered the price target on the stock from $40 to $35, while keeping a Buy rating.

The mixed outlook follows the company’s fiscal Q3 2025 results, announced on November 6. The revenue grew 99.71% year-over-year to $956.05 million, surpassing estimates by $3.22 million. However, the EPS of $0.01 fell short of the consensus by $0.43. Management attributed the growth to being driven by the integration of Prospect Health into the company, followed by solid organizational growth across its core business.

However, looking ahead, management is expecting headwinds in its Medicaid and exchange business. Therefore, Astrana Health, Inc. (NASDAQ:ASTH) lowered its full-year revenue guidance to a range of $3.1 billion and $3.18 billion, down from the previous range of $3.1 billion to $3.3 billion. The Adjusted EBITDA guidance was also lowered to a range of $200 million and $210 million from the previous range of $215 million and $225 million.

The analyst Ryan Langston of TD Cowen noted that this reduced outlook reflects caution on Medicaid and the VBC environment.

Astrana Health, Inc. (NASDAQ:ASTH) is a physician-centered, technology-powered healthcare company that focuses on delivering coordinated, high-quality care to patients through its network of providers.

Disclosure: None. This article is originally published at Insider Monkey.